Establishment of a regression model of bone metabolism markers for the diagnosis of bone metastases in lung cancer

Abstract Background The aim of this study was to establish a regression equation model of serum bone metabolism markers. We analyzed the diagnostic value of bone metastases in lung cancer and provided laboratory evidence for the early clinical treatment of bone metastases in lung cancer. Methods A t...

Full description

Bibliographic Details
Main Authors: Zhongliang Zhu, Guangyu Yang, Zhenzhen Pang, Jiawei Liang, Weizhong Wang, Yonglie Zhou
Format: Article
Language:English
Published: BMC 2021-01-01
Series:World Journal of Surgical Oncology
Subjects:
Online Access:https://doi.org/10.1186/s12957-021-02141-5
_version_ 1818578506632658944
author Zhongliang Zhu
Guangyu Yang
Zhenzhen Pang
Jiawei Liang
Weizhong Wang
Yonglie Zhou
author_facet Zhongliang Zhu
Guangyu Yang
Zhenzhen Pang
Jiawei Liang
Weizhong Wang
Yonglie Zhou
author_sort Zhongliang Zhu
collection DOAJ
description Abstract Background The aim of this study was to establish a regression equation model of serum bone metabolism markers. We analyzed the diagnostic value of bone metastases in lung cancer and provided laboratory evidence for the early clinical treatment of bone metastases in lung cancer. Methods A total of 339 patients with non-metastatic lung cancer, patients with lung cancer with bone metastasis, and patients with benign lung disease who were treated in our hospital from July 2012 to October 2015 were included. A total of 103 patients with lung cancer in the non-metastatic group, 128 patients with lung cancer combined with bone metastasis group, and 108 patients with benign lung diseases who had nontumor and nonbone metabolism-related diseases were selected as the control group. Detection and analysis of type I collagen carboxyl terminal peptide β-special sequence (β-CTX), total type I procollagen amino terminal propeptide (TPINP), N-terminal-mid fragment of osteocalcin (N-MID), parathyroid hormone (PTH), vitamin D (VitD3), alkaline phosphatase (ALP), calcium (CA), phosphorus (P), cytokeratin 19 fragment (F211), and other indicators were performed. Four multiple regression models were established to determine the best diagnostic model for lung cancer with bone metastasis. Results Analysis of single indicators of bone metabolism markers in lung cancer was performed, among which F211, β-CTX, TPINP, and ALP were significantly different (P < 0.05). The ROC curve of each indicator was less than 0.712. Based on the multiple regression models, the fourth model was the best and was much better than a single indicator with an AUC of 0.856, a sensitivity of 70.0%, a specificity of 91.0%, a positive predictive value of 82.5%, and a negative predictive value of 72.0%. Conclusion Multiple regression models of bone metabolism markers were established. These models can be used to evaluate the progression of lung cancer and provide a basis for the early treatment of bone metastases.
first_indexed 2024-12-16T06:46:54Z
format Article
id doaj.art-d1df02cf391f461982e214e07b3a60bc
institution Directory Open Access Journal
issn 1477-7819
language English
last_indexed 2024-12-16T06:46:54Z
publishDate 2021-01-01
publisher BMC
record_format Article
series World Journal of Surgical Oncology
spelling doaj.art-d1df02cf391f461982e214e07b3a60bc2022-12-21T22:40:32ZengBMCWorld Journal of Surgical Oncology1477-78192021-01-011911610.1186/s12957-021-02141-5Establishment of a regression model of bone metabolism markers for the diagnosis of bone metastases in lung cancerZhongliang Zhu0Guangyu Yang1Zhenzhen Pang2Jiawei Liang3Weizhong Wang4Yonglie Zhou5Department of Clinical Laboratory, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical CollegeDepartment of Clinical Laboratory, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical CollegeDepartment of Clinical Laboratory, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical CollegeDepartment of Clinical Laboratory, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical CollegeDepartment of Clinical Laboratory, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical CollegeDepartment of Clinical Laboratory, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical CollegeAbstract Background The aim of this study was to establish a regression equation model of serum bone metabolism markers. We analyzed the diagnostic value of bone metastases in lung cancer and provided laboratory evidence for the early clinical treatment of bone metastases in lung cancer. Methods A total of 339 patients with non-metastatic lung cancer, patients with lung cancer with bone metastasis, and patients with benign lung disease who were treated in our hospital from July 2012 to October 2015 were included. A total of 103 patients with lung cancer in the non-metastatic group, 128 patients with lung cancer combined with bone metastasis group, and 108 patients with benign lung diseases who had nontumor and nonbone metabolism-related diseases were selected as the control group. Detection and analysis of type I collagen carboxyl terminal peptide β-special sequence (β-CTX), total type I procollagen amino terminal propeptide (TPINP), N-terminal-mid fragment of osteocalcin (N-MID), parathyroid hormone (PTH), vitamin D (VitD3), alkaline phosphatase (ALP), calcium (CA), phosphorus (P), cytokeratin 19 fragment (F211), and other indicators were performed. Four multiple regression models were established to determine the best diagnostic model for lung cancer with bone metastasis. Results Analysis of single indicators of bone metabolism markers in lung cancer was performed, among which F211, β-CTX, TPINP, and ALP were significantly different (P < 0.05). The ROC curve of each indicator was less than 0.712. Based on the multiple regression models, the fourth model was the best and was much better than a single indicator with an AUC of 0.856, a sensitivity of 70.0%, a specificity of 91.0%, a positive predictive value of 82.5%, and a negative predictive value of 72.0%. Conclusion Multiple regression models of bone metabolism markers were established. These models can be used to evaluate the progression of lung cancer and provide a basis for the early treatment of bone metastases.https://doi.org/10.1186/s12957-021-02141-5Bone metabolism markersLung cancerBone metastases
spellingShingle Zhongliang Zhu
Guangyu Yang
Zhenzhen Pang
Jiawei Liang
Weizhong Wang
Yonglie Zhou
Establishment of a regression model of bone metabolism markers for the diagnosis of bone metastases in lung cancer
World Journal of Surgical Oncology
Bone metabolism markers
Lung cancer
Bone metastases
title Establishment of a regression model of bone metabolism markers for the diagnosis of bone metastases in lung cancer
title_full Establishment of a regression model of bone metabolism markers for the diagnosis of bone metastases in lung cancer
title_fullStr Establishment of a regression model of bone metabolism markers for the diagnosis of bone metastases in lung cancer
title_full_unstemmed Establishment of a regression model of bone metabolism markers for the diagnosis of bone metastases in lung cancer
title_short Establishment of a regression model of bone metabolism markers for the diagnosis of bone metastases in lung cancer
title_sort establishment of a regression model of bone metabolism markers for the diagnosis of bone metastases in lung cancer
topic Bone metabolism markers
Lung cancer
Bone metastases
url https://doi.org/10.1186/s12957-021-02141-5
work_keys_str_mv AT zhongliangzhu establishmentofaregressionmodelofbonemetabolismmarkersforthediagnosisofbonemetastasesinlungcancer
AT guangyuyang establishmentofaregressionmodelofbonemetabolismmarkersforthediagnosisofbonemetastasesinlungcancer
AT zhenzhenpang establishmentofaregressionmodelofbonemetabolismmarkersforthediagnosisofbonemetastasesinlungcancer
AT jiaweiliang establishmentofaregressionmodelofbonemetabolismmarkersforthediagnosisofbonemetastasesinlungcancer
AT weizhongwang establishmentofaregressionmodelofbonemetabolismmarkersforthediagnosisofbonemetastasesinlungcancer
AT yongliezhou establishmentofaregressionmodelofbonemetabolismmarkersforthediagnosisofbonemetastasesinlungcancer